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Human rIL-4 was studied for its capacity to induce 
lymphokine-activated killer (LAK) cell activity. In 
contrast to IL-2, IL-4 was not able to induce LAK 
cell activity in cell cultures derived from peripheral 
blood. IL-4 added simultaneously with IL-2 to such 
cultures suppressed IL-2-induced LAK cell activity 
measured against Daudi and the melanoma cell line 
ME WO in a dose-dependent way. IL-4 also inhibited 
the induction of LAK cell activity in CD2+, CD3~, 
CD4”, CD8~ cells» suggesting that IL-4 acts directly 
on LAK precursor cells. IL-4 added 24 h after the 
addition of IL-2 failed to inhibit the generation of 
LAK cell activity. Cytotoxic activity of various types 
of NK cell clones was not affected after incubation 
in IL-4 for 3 days, indicating that IL-4 does not affect 
the activity of already committed killer cells. No 
significant differences were observed in the per­
centages of Tac*, NKH-1+ and CD16* cells after cul­
turing PBL in IL-2, IL-4 or combinations of IL-2 and 
IL-4 for 3 days. IL-4 also inhibited the activation of 
non-specific cytotoxic activity in MLC, as measured 
against K-562 and MEWO cells. In contrast, the Ag- 
specific CTL activity against the stimulator cells 
was augmented by IL-4. Collectively, these data in­
dicate that IL-4 prevents the activation of LAK cell 
precursors by IL-2, but does not inhibit the genera­
tion of Ag-specific CTL*
IL-2 has the ability to activate a killer cell population 
of PBL (1-6) and thymocytes (7-9). These LAK2 cells are 
able to lyse fresh tumor cells as well as cells from in vitro 
tumor cell lines that are not lysed by freshly isolated NK 
cells. It has been shown recently that both the precursors 
and the effector cells have the characteristics of NK cells 
(4-6). It was demonstrated that the majority of the LAK 
cell activity is mediated by NKH-1* cells that do not 
express CD3 and that the precursors of these cells have 
the same phenotype (5, 6). In addition, there appears to 
be some contribution of CD3+, NKH-1+ T cells to the LAK 
cell activity induced from PBL, but the kinetics of ap­
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pearance of LAK cell activity mediated by these cells is 
delayed compared with the LAK cell activity mediated by 
CD3", NKH-1* cells (5, 6). Little is known about the 
mechanism of induction of LAK cell activity. It has been 
reported that activation of NK cells by IL-2 is not inhibited 
by mAb against the 55-kDa Tac Ag, whereas these anti­
bodies block T cell proliferation (10, 11). This suggests 
that induction of LAK cell activity involves a different IL- 
2 R than T cell proliferation. Indeed, evidence has been 
obtained that IL-2 activates NK cells via a 73-kDa peptide 
that binds IL-2 with an intermediate affinity (12-14). 
The high affinity IL-2R appears to consist of a complex 
of the Tac Ag with the 73-kDa protein (15).
Recently, a cDNA clone that encodes human IL-4 has 
been obtained from the human T cell clone 2F1 (16). We 
reported that human rIL-4 can support the growth of 
human T cells and that the growth-promoting activity of 
IL-4 was not restricted to a certain subset of T cells (17). 
CD3* as well as CD3~ T cell clones could respond to IL-4 
(17). These findings raised the question of whether IL-4 
could also induce LAK cell activity. In this paper, we 
investigate the effect of IL-4 on the induction of cytolytic 
activity of human cells against the lymphoblastoid Burk- 
itt lymphoma line Daudi and against the short term cul­
tured melanoma cell line MEWO. It was found that IL-4 
was not only unable to induce cytotoxic activity, but that 
it inhibited the IL-2-mediated induction of cytolytic activ­
ity against these cell lines. IL-4 was also found to block 
non-specific cytotoxicity generated in a MLC. In contrast, 
MLC-generated Ag-specific cytotoxicity was augmented 
by IL-4.
MATERIALS AND METHODS
IL. An IL-4-encodlng cDNA clone w as isolated from a  cDNA library 
of the  hum an helper T cell clone 2F1 [16), Cos-7 monkey kidney 
cells were transfected  w ith th is cDNA clone in a m am m alian expres­
sion vector, and  superna tan ts  containing IL-4 were harvested after 
48 h (16). One u n it of IL-4 is defined as the am ount of IL-4 required 
to cause half-m axim al proliferation of 2 x 104 PHA-preactivated T 
cells. In some experim ents, IL-4 from Cos-7 supernatan ts, partially 
purified by passage over S-Sepharose and  Sephadex G-100 columns 
w as used.
The IL-2 preparation was a n  Escherichia  coZi-produced IL-2. The 
biologic activity of IL-2 w as determ ined by using the IL-2-dependent 
m urine T cell line CTLL-2, as described by Gillis et al. (18).
Preparation o f  lym phocyte  popu la tions , PBL were isolated from 
healthy donors by Ficoll-Hypaque density gradient centrifugation. 
To enrich for CD3~ cells, PBL were firs t rosetted with SRBC a t a 
lymphocyte to SRBC ratio of 1:50 for 15 h at 4°C in a modification 
of Iscoves medium (Gibco Laboratories, Glasgow, Scotland), de­
scribed by Yssel et al. (19), containing \  % hum an AB+ serum. The 
rosetted cells were centrifuged through a. Ficoll-Hypaque gradient, 
followed by lysis of the  SRBC In an  isotonic NH4C1 buffer for 10 min
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at 4°C. The cells ( 5 x 1 07/ml) were washed twice and incubated with 
a 1/100 dilution of the anti-CD3 mAb SPV-T3b for 1 h at 4°C. After 
three washes, the cells were Incubated for 20 min with HRBC coated 
with GAM using CrCl3 as described previously (20). After vortexing, 
the cells were depleted from the rosette-forming (CD3+) cells by 
centrifugation over Ficoll-Hypaque. The CD3~ population w as also 
negative for CD4 and CD8 and  reacted weakly w ith the mAb NKH-
1. Alternatively, PBL were incubated for 45 min a t 37°C in tissue 
culture flasks (Falcon; Becton Dickinson, M ountain View, CA) to 
remove adherent cells. Subsequently, the non-adherent cells were 
incubated w ith a  m ixture of the  anti-CD8 mAb SPV-T8 and the anti- 
0 0 4  mAb RIV-6 , The CD4+ and CD8+ cells were removed with the 
reversed rosetting method described above. The rem aining cells 
contained 5 to 10% CD3+ cells, bu t were virtually negative for CD4 
and CD8 , as  determined with a  FACS 440 (Becton Dickinson).
C ultures/or induction o f LAK cell activity. PBL or subpopulations 
of PBL were usually incubated with 20 U/ml IL-2 at a  concentration 
of 106 cells/m l for 3 days in Yssel’s medium containing 1% hum an 
AB* serum. The cultures were performed in 1-ml wells of a Linbro 
24-well plate (Flow Laboratories, McLean, VA). After the  culture 
period, the  cells were harvested and washed twice before use.
MLC. PBL (106/ml) were cultured w ith allogeneic irradiated (3000 
rad) PBL a t a  responder to stim ulator ratio of 1:1 in Yssel’s  medium 
plus 1% AB+ serum  for 6 days in 1-ml wells of a  24-well Linbro plate. 
The cells were harvested, w ashed twice, and used as effector cells 
in a 5'C r release assay. For a secondary MLC, the responder cells 
were washed 10 days a fte r the onset of the primary MLC and 
restim ulated with the irradiated stim ulator cells a t a  1 : 1  ratio under 
the sam e conditions as used for the prim ary MLC, except th a t the 
m ixtures were incubated for 4  days before testing the responder 
cells. PBL of the stim ulator cell type th a t w ere stim ulated 4 days 
before the test with 0,1 1 purified PHA (Wellcome, Beckenham, 
England), were used as target cells.
51 Or release a s s a y . The 51 Cr release assay  was carried out as 
described previously (21). Briefly, 1000 51Cr-labeIed target cells were 
mixed with varied num bers of effector cells in Iscove’s medium 
containing 0,25% BSA (Sigma Chemical Co,, St. Louis, MO). The 
tests were carried out in U-shaped 96-well Linbro plates. The plates 
were centrifuged for 5 min at 50 X g  before an  incubation for 4 h a t 
37°C in a humidified 5% COz atm osphere. T he sam ples were har­
vested by using a Skatron harvester (Lier, Norway) and counted in a 
gamma counter (LKB, Bromma, Sweden).
Target cells. The cell lines used in th is  study were the erythroid/ 
myeloid cell line K-562, th e  B urkitt lym phom a line Daudl, and the 
melanoma cell line MEWO. These cell lines were cultured in Yssel’s 
medium containing 1% AB+ hum an  serum .
E stab lishm ent o f LAK cell clones . Clone WM-14 has been isolated 
from WT-31" cord blood cells as has been described previously (22). 
The clone expresses TCR7 , which is associated w ith the CD3 com­
plex and reacts with anti-TCR51 (23). WM-14 does not express CD4 
or CD8, but is positive for NKH-1. Clone HY-133 (CD3+, WT-31+, 
CD4", CD8+, NHK-1+) has been described previously (22). Clone HY- 
212 is a  CD3" clone derived from th e  sam e cloning as clone HY-133. 
The clones NL-5 (CD3+, WT-31", TCR51+), NL-1 (CD3"), and NL-6 
(CD3') are derived from peripheral blood T cells th a t were depleted 
of CD4+ and CD8+ cells by reversed rosetting. The clones were 
m aintained by weekly stim ulations in  a  feeder cell m ixture contain­
ing irradiated PBL (4000 rad), irradiated EBV-transformed B cells 
(5000 rad), and PHA (0.1 /¿g/ml) as described previously for cloned 
allospecific CTL (21). The clones were cultured in  Yssel’s medium.
mAb. The mAb used in th is study for separation by m eans of 
reversed rosetting and for phenotyping were SPV-T3b (anti-CD3) 
(24), RIV-6 (anti-CD4; a  kind gift from Dr. Kreeftenberg, National 
Institute of Health (RIV), Bilthoven, The Netherlands), the anti-CD8 
mAb SPV-T8 (4), WT-31 (anti-TGRa, /?) (25), NHK-1 (reacts w ith NK 
cells; purchased from Coultronics, Margency, France) (26), and Leu
11 (anti-CD16, Becton Dickinson). The anti-Tac mAb, IOT-14 (27), 
w as purchased from Im m unotech (Luminy, Marseille, France). The 
anti-TCR<51 antibody th a t reacts w ith a  fram ew ork determ inant on 
the TCRS chain (23) was a kind gift from Dr. M. B renner (Dana 
Farber Cancer Institute, Boston, MA).
Phenotyping o f cell sam ples. The separated cell sam ples and T 
cell clones were typed for the expression of cell surface Ag by flow 
cytometry. The sam ples were labeled with mAb and FITC-labeled 
GAM F(ab ')2 fragm ents (Grub, V ienna, Austria) as described previ­
ously (21). The sam ples were analysed with a FACS-440.
RESULTS
The effect of IL-4 on the induction of LAK cells. 
Freshly isolated PBL were incubated with IL-2, with IL-4 
semi-purified from Cos-7 monkey kidney cell superna-
tants (see Materials and Methods), or with combinations 
of IL-2 and IL-4. Strong LAK cell-mediated cytotoxicity 
induced by IL-2 was observed at an E:T cell ratio of 30:1. 
Freshly isolated PBL or PBL cultured in medium only 
were ineffective in lysing Daudi or MEWO cells. In Figure 
1 it is shown that IL-4, in contrast to IL-2, was unable to 
induce cytotoxic activity against Daudi cells (Fig. I A) or 
against the melanoma cell line MEWO (Fig. IB). Strik­
ingly, It was observed that IL-4 reduced the level of LAK 
cell activity induced by IL-2 when these lymphokines 
were added simultaneously to the PBL. In Figure 1A it is 
shown that the inhibiting effection of IL-4 was dose 
dependent. Approximately 50% inhibition was observed 
at an IL-4 concentration of 20 U/ml. The LAK cell activity 
generated by IL-2 against MEWO was already completely 
blocked by 20 U/ml IL-4 (Fig. IB). The results in Figure
1, A and B reflect the general finding that the IL-2- 
induced LAK cell activity against MEWO cells is more 
sensitive to blocking with IL-4 than the activity against 
Daudi, The reason for this difference in sensitivity is 
presently unclear.
The effect of IL-4 on induction of LAK cell activity in 
CD2+, CD3~ precursor cells. The results presented in 
Figure 1 indicate that IL-4 inhibits the generation of LAK 
cell activity mediated by IL-2. To determine whether IL-4 
acts directly on the precursor cell, induces the generation
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Figure L The effect of purified IL-4 on the induction of cytotoxic 
activity and IL-2-induced LAK cell activity against Daudi cells (A) and 
MEWO cells (B). □, Medium control; ♦, IL-4 (200 U/ml); □, IL-4 (20 U/ml); 
O, IL-2; ■, IL-2 plus IL-4 (200 U/ml); and D, IL-2 plus IL-4 [20 U/ml). IL-2 
was added at a concentration of 20 U/ml. The IL-4 used in this experiment 
was semi-purified from Cos-7 supematants as indicated in Materials and 
Methods.
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of suppressor T cell activity, or, alternatively, induces 
the synthesis of an inhibitory factor from mature T cells, 
CD3~ cells were isolated from CD2+ cells by using a two- 
step separation procedure. In the first experiment shown 
in Table I, non-adherent, SRBC rosette-positive T cells 
were incubated for 1 h with the anti-CD3 mAb SPV-T3b. 
The CD3+ cells were subsequently removed by rosetting 
with GAM-labeled HRBC, followed by centrifugation over 
a Ficoll-Hypaque gradient. Less than 2% of the interface 
cells expressed CD3 as determined by flow cytometry. In 
Table I it is shown that IL-2 could induce a high cytotoxic 
activity in the CD3“ cell population. IL-4-containing Cos-
7 supernatant strongly blocked the induction of this LAK 
cell activity. The same results were obtained with CD4”, 
CD8- cells that were obtained after removal of the CD4+ 
and CD8+ cells from non-adherent PBL by the same 
procedure. In that case, the non-adherent cells were in­
cubated with a mixture of anti-CD4 and anti-CD8 mAb, 
followed by rosetting with GAM-labeled HRBC (Table I). 
Although not shown, supernatants of mock-transfected 
Cos-7 cells have no effect on IL-2-induced LAK cell activ­
ity. These results suggest that IL-4 inhibits the induction 
of LAK cell activity at the level of the precursor cell.
The effects of sequential addition of IL-2 and IL-4 on 
the induction of LAK cell activity in PBL. The results of 
the experiments shown in Table I suggest that the inhi­
bition of LAK cell generation by IL-4 is not an indirect 
effect. It was, however, not clear whether the inhibition 
of LAK cell activity is based on the inhibition of the 
inducing event itself or on the inactivation of the effector 
cells mediating the cytolytic activity. In the latter case, 
we would expect that incubation with IL-4 of cells that 
are already activated with IL-2 would inhibit their lytic 
activity. In Table II it is shown that the addition of IL-4 
24 h after the addition of IL-2 did not affect the lytic 
activity of the activated killer cells, whereas simultane­
ous addition of IL-4 and IL-2 strongly inhibited this activ­
ity.
In a second set of experiments, we investigated the
TABLE I
Effect of IL-4 on IL-2-mediated induction of LAK celt activity in CD4~ 
CD8~ and CD3~ cells isolated from PBL against ME WO cells
Cell Population“ Lymphokine Addedb
%
1:1
51Cr Release at an E:T 
Ratio of
3:1 10:1 30:1
Expt. 1
PBL None ND 0 1 2
IL-2 ND 6 15 28
IL-4 ND 0 1 0
IL-2 -1- IL-4 ND 4 6 13
CD4" CD8“ None ND 0 0 6
IL-2 ND 18 33 54
IL-4 ND 0 0 0
IL-2 + IL-4 ND 5 9 22
Expt. 2
CD3- None 2 3 10 ND
IL-2 47 58 70 ND
IL-4 1 2 5 ND
IL-2 4- IL-4 16 24 34 ND
“ The CD4~CD8" and the CD3” cells were obtained as described In
Materials and Methods. The CD4”CD8“ cell sample In experiment 1 
contained 10% CD3+ cells and no CD4+ or CD8+ cells, whereas the CD3" 
cell sample in experiment 2 contained 3% CD3+ cells.
b IL-2 was added at a concentration of 20 U/ml. The concentration of 
IL-4 in experiment 1 was 100 U/ml [2% of supernatant of Cos-7 cells 
transfected with IL-4 cDNA, containing 5000 U/ml). In experiment 2, the 
IL-4 was purified from transfected Cos-7 supernatants and used at a 
concentration of LOG-U/ml.
Effect o f sequential addition o f IL-4 on the lL-2-tnduced LAK cell
activity in PBL against MEWO cells
TABLE II
% 51Cr Release at an
Lymphokine Added® E:T Ratio of
30:1 10:1
Medium 11 7
IL-2 47 29
11-2 + IL-4 5 3
IL-2 + IL-4 a t  24 h b 46 29
a The concentration of IL-2 used in this experiment was 20 U/ml, IL-4 
(100 U/ml final concentration) was added as a supernatant of transfected 
Cos-7 cells, as in Table I.
b IL-4 was added 24 h after the addition of IL-2.
TABLE III
Effect o f pre-incubation of PBL in IL-4 fo r  24 h on the subsequent 
induction of LAK cell activity by IL-2 or IL-2 plus IL-4
LU/103 Cel Isc
Pre-incubation” Incubation0
Daudi MEWO
Medium Mediumd <1 <1
IL-4 < 1 <1
IL-2 17 7
IL-2 + IL-4 3 < 1
IL-4 Mediumd <1 <1
IL-4 <1 < 1
IL-2 17 5
IL-2 + IL-4 2 <1
a PBL (I0e) were pre-incubated in 100 U/ml IL-4 or medium for 24 h.
bIL-2 and IL-4 were added at concentrations of 20 and 100 U/ml, 
respectively.
c One LU was defined as the number of effector cells necessary to cause 
30% specific &1Cr release of 103 target cells. LU were calculated from a 
dose-response curve In which the percent51 Cr release was plotted against 
the E:T ratios 90:1, 30:1, 10:1, and 3:1.
a Cell recoveries were similar for all cultures.
possibility that pre-incubation with IL-4 somehow inac­
tivates the precursor of the cells that mediate non-spe­
cific cytotoxic activity. PBL (106/ml) were incubated in 
medium or in 100 U/ml IL-4 for 24 h, then washed three 
times, and incubated for 3 days in medium alone or 
containing IL-2, IL-4, or IL-2 plus IL-4. It is shown in 
Table III that IL-2 induced LAK cells with a cytotoxic 
activity of 17 and 7 LU/105 cells, respectively, against 
Daudi and MEWO cells. This activity was reduced to 2 
and <1 LU/105 cells, respectively, when IL-2 was added 
together with IL-4. The PBL pre-incubated in IL-4 and 
subsequently cultured in IL-2 had the same cytotoxic 
activity against Daudi cells (17 LU/105 cells) as the PBL 
pre-incubated in medium, whereas the activity against 
MEWO was slightly reduced (5 LU/10B cells) in the PBL 
pre-incubated with IL-4. These results demonstrate that 
24 h of pre-incubation in IL-4 does not inactivate the 
LAK cell precursors.
The effect of IL-4 and IL-2 on the cytolytic activity of 
NK clones. To further determine whether IL-4 can affect 
the lytic activity of already committed killer cells, we 
tested the effect of incubation with IL-4 on the cytolytic 
activity of activated killer cell clones. The clones NL-1 
and NL-6 (CD3- , NHK-1+, Leu 1 1+), clones NL-5 and WM 
14 (CD3+, WT-31~, TCR51+, NKH-1+, Leu 11"), and clone 
HY-133 (CD3+, WT-31+, TCRS1“, NKH-1+, Leu 11') rep­
resent the various subpopulations of LAK cells as de­
scribed by Phillips and Lanier (5) (Table IV). All these 
clones were cytotoxic for Daudi cells. Previously, we have 
found that IL-4 could promote the growth of such clones 
(17). Six days after stimulation with feeder cells, the 
activated killer clones were washed extensively and in-
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Effect of incubation in IL-2, IL-4, and IL-2 plus IL-4 on the cytolytic
activity of NK clones against Daudi cells
TABLE IV
Clone Phenotype Incubation“
% 51Cr 
Release at 
an E:T Ratio 
of
30:1 3:1
NL-1 CD3", NHK~1+, Leu 11 + IL-2 35 17
IL-4 31 17
IL-2 + IL-4 42 21
NL-5 CD3+ WT31~, NKH-1 IL-2 64 50
TC R U \ Leu 11’
IL-4 62 55
IL-2 + IL-4 66 47
NL-6 CD3", NKH-1'1', Leu l l  + IL-2 41 21
IL-4 51 30
IL-2 + IL-4 48 19
WM -14 CD3+, WT31", NKH-1\ IL-2 59 37
TCR51+, Leu 1 1 *
IL-4 73 48
IL-2 + IL-4 70 20
HY-133 CD3^, WT31+, NKH-1*. IL-2 41 21
Leu 1.1“
IL-4 39 18
IL-2 + IL-4 45 19
a The clones were washed two times 6 days after stimulation with 
feeder cells and were incubated with the lymphokines for another 3 days* 
IL-2 and IL-4 were added at concentrations of 40 and 100 U/ml, respec­
tively.
TABLE V
Effect of culturing PBL in IL-2t IL-4, and IL-2 plus IL-4 for 3 days on
the phenotype of PBL
% of Positive Cells 
After Culture in fl
Medium IL-2 IL-4 IL-2 + IL-4
SPV-T3b 62 62 65 61
WT-31 61 60 60 60
NKH-1 5 6 6 7
Leu 11 10 10 13 17
IOT-14 [anti-Tac) 2 6 2 4
Q IL-2 and IL-4 were added at concentrations of 40 and 100 U/ml, 
respectively. The cell concentration in the cultures was 106 cells/ml.
cubated in IL-2, IL-4, or IL-2 plus IL-4 for three days. In 
Table IV it is shown that none of these clones lost their 
cytolytic activity against Daudi cells upon incubation in 
IL-2, IL-4, or a mixture of IL-2 and IL-4. One of the clones, 
WM-14, was also cytotoxic for MEWO cells. The activity 
of WM-14 against MEWO was not affected by incubation 
in IL-4 (results not shown).
Taken together, these results indicate that pre-incu­
bation of PBL in IL-4 for 24 h does not inactivate the 
precursor cell nor the effector cell that mediates activated 
killer cell activity. Moreover, IL-4 appears to inhibit the 
generation of LAK cell activity only when It is added 
simultaneously with IL-2 to the PBL, indicating that IL-4 
somehow prevents the activation event mediated by IL- 
2.
The effects of IL-4 and IL-2 on the phenotype of short 
term cultured PBL. The results of the previous experi­
ments suggest that IL-4 prevents the IL-2-induced acti­
vation of the precursors of LAK cells. To further investi­
gate this point, we compared the phenotype of PBL cul­
tured in IL-2, IL-4, IL-2 plus IL-4, or medium only. In 
Table V it is shown that after 3 days of culture no 
differences in the phenotype of the PBL in the four cul­
tures could be detected. The finding that no significant
differences in the distribution of NKH-1 and Leu 11 were 
observed after 3 days indicates that the inhibition of the 
generation of LAK cell activity by IL-4 is not due to a 
selective disappearance of NKH-1+ or CD 16+ cells in the 
first 3 days.
The effect of IL-4 on the activity of NK cells against 
K-562. In view of the discussion about the relationship 
between LAK cells and NK cells, it was of interest to 
know which effect IL-4 has on the constitutive NK cell 
activity and whether IL-4 can inhibit the enhancement 
of NK activity by IL-2 (10, 28). To this end, PBL were 
cultured for 48 h with 100 U/ml IL-4, 20 U/ml IL-2, or a 
combination of these lymphokines, It is shown in Table 
VI that IL-4 does not affect the constitutive cytotoxic 
activity against K-562, but blocked the IL-2-mediated 
enhancement of this activity. These findings support the 
notion that once there is a non-specific (NK-like) cytotoxic 
activity, incubation for a limited period of time in IL-4 
does not inhibit this activity. Moreover, IL-4 inhibited the 
IL-2-mediated enhancement of NK activity against K- 
562.
The effect of IL-4 on cytotoxic activities generated in 
MLC. The data thus far indicate that IL-4 inhibits IL-2- 
induced cytotoxic activity. Recently it has been reported 
that murine IL-4 augmented the cytotoxic activity of mu­
rine CTL generated in an in vitro MLC (29). It has been 
demonstrated that, in addition to specific CTL activity, 
non-specific cytotoxic activity is also generated in a MLC 
(30). It was of interest therefore to compare the effects of 
IL-4 on the generation of specific and non-specific cyto­
toxic activities in the human system. In Figure 2 it is 
shown that administration of IL-4 to a MLC augmented 
the cytotoxic activity of the MLC responder cells against 
the PHA-pre-activated cells of the stimulator cell type 
(Fig. 2A). IL-2 at 20 U/ml hardly affected the cytotoxic 
activity against the specific stimulator cells on a per cell 
basis, but enhanced the cytotoxicity against MEWO (Fig. 
2B) and K-562 (Fig. 2C). In contrast, IL-4 blocked the 
generation of cytolytic activity against K-562 and MEWO 
cells. It should be noted here that the cell recoveries of 
the cultures in IL-2 and IL-4 were comparable and only 
slightly higher (10 to 20%) than those of the MLC cultured 
in medium only (data not shown). IL-4 also stimulated 
the specific cytotoxicity, but blocked the non-specific 
cytotoxicity, in secondary MLC. PBL were stimulated with 
irradiated allogeneic PBL. Ten days later, 106 responder 
PBL/ml were restimulated with 106 irradiated stimulator 
PBL/ml in medium or in medium supplemented with 20 
U/ml IL-2 or 100 U/ml IL-4. The recoveries of these 
cultures after 4 days were 1.2 X 106 T cell blasts/ml in 
medium, 3.2 x 106 T cell blasts/ml in IL-2, and 5 x 106 
T cell blasts/ml in IL-4.
In Figure 3 it is shown that on a per cell basis the
TABLE VI
Bffect of IL-4 on NK cell activity against K-562 and the enhancement
of NK cell activity induced by IL-2a
% 51Cr Release at an E:T Ratio of
60:1 20:1 6:1 2:1
C on tro l 24 12 4 0
IL-4 23 10 4 1
IL-2 76 50 29 10
IL-2 4- IL-4 53 37 7 3
a PBL (10s/ml) were Incubated for 48 h in medium with or without 100 
U/ml IL-4, 20 u/m l IL-2, or a combination of these lymphokines.
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Figure 2. The effects of additions of IL-2 (20 U/ml) and IL-4 (100 U/  
ml) on cytotoxic activities generated against PH A blasts of the stimulator 
cell type (A), K-562 (B), and MEWO (C). The PH A blasts were obtained 
by stimulation of the PBL with 0.1 fig of purified PHA for 4 days. None of 
the cultures were cytotoxic for the PHA blasts of the responder cell type.
10:1 30:1 60:1
Effector to target cell ratio
Figure 3. The effects of IL-2 and IL-4 on cytotoxic activities generated 
in secondary MLC. The cytotoxic activities were determined 6 days after 
initiation of the primary MLC and 4 days after the onset of the secondary 
MLC (see Materials and Methods). The cytotoxic activities of the primary 
MLC blasts at an E:T ratio of 30:1 were 7% against PHA blasts of the 
stimulator cell type, 15% against MEWO, and 34% against K-562. The 
cell recoveries of the secondary MLC were 1.3 X 1O0 cells/ml in medium, 
3.2 x 106 cells/ml in IL-2 (20 U/ml) and 5 x 10a cells/ml In IL-4 (100 U/ 
ml). The secondary MLC T blasts were tested against PHA blasts of the 
stimulator cell type (A), K-562 (B), and MEWO (C).
cytotoxic activity of the T cell blasts against the PHA 
blasts of the stimulator cell type is similar for the cells 
cultured in medium compared with those cultured in IL- 
2, but inasmuch as the IL-2-supplemented culture con­
tained approximately 3 times more cells than the cultures 
incubated in medium only, IL-2 enhanced the specific 
CTL activity per culture. IL-4 enhanced the specific CTL 
activity both per cell as well as per culture. It is shown in 
Figure 3, B and C, that IL-4 completely abrogated the 
non-specific cytotoxic activities against K-562 and 
MEWO, respectively, whereas IL-2 enhanced these activ­
ities. These results demonstrate that IL-4 also blocks the 
generation of Ag-non-specific cytotoxic activity in a MLC, 
whereas it augments the Ag-specific cytotoxic activity.
DISCUSSION
Recently, we have found that IL-4 can promote the 
growth of mature CD4+ and CD8+ T cells, as well as of 
CD3~ NK clones (17). It was therefore of interest to know 
whether IL-4, like IL-2, could also induce activated killer 
cell activity. It is reported here that IL-4 does not induce 
activated killer cells. On the contrary, we observed that 
IL-4 inhibits the induction of activated killer cells by IL-
2. We did not test the activity of the killer cell populations 
activated in our system against fresh tumor cells. One of 
the target cells used in these studies, however, is a mel­
anoma cell line (MEWO) in an early passage after estab­
lishment. We consider it therefore very likely that our 
observations reflect the inhibition by IL-4 of the indue-
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tion of LAK cell activity (defined a priori as an activity 
against fresh tumor cells). Interestingly, IL-4 also inhib­
ited the augmentation of NK cell activity by IL-2 as meas­
ured against K-562, but did not affect the constitutive 
NK cell activity after an incubation of PBL for 48 h.
The finding that depletion of mature T cells from PBL 
does not affect the inhibition by IL-4 of IL-2-mediated 
induction of LAK cells excludes the possibility that IL-4 
induces the production of inhibitory factors by mature T 
ceils. Our data, rather, suggest that IL-4 inhibits the 
induction of LAK cell activity directly at the level of the 
precursor cell. It can presently not be excluded that the 
effect of IL-4 is an indirect one, namely, inducing the 
production of inhibitory factors by the LAK precursor 
itself or by a cell type that is neither a T cell nor a LAK 
precursor, but which co-purified with the LAK precursor 
cells. It is clear from the data presented in Table III that 
pre-incubation of PBL in IL-4 for 24 h does not inactivate 
the cytotoxic precursor cells, inasmuch as PBL pre-in- 
cubated in IL-4, washed, and subsequently incubated in 
IL-2 develop activated killer cell activity to an extent 
similar to the PBL pre-incubated in medium for 24 h.
Once the effector cells mediating LAK cell activity are 
generated, IL-4 does not affect the cytolytic activity. In 
the first place, it was found that IL-4, added 24 h after 
addition of IL-2, does not affect the subsequent develop­
ment of LAK cell activity. Secondly, incubation in IL-4 of 
cloned lines of killer cells that had the phenotypic char­
acteristics of LAK cells (5, 6) does not alter the cytotoxic 
activity measured against the LAK cell-sensitive target 
cell Daudi. Our findings suggest that IL-4 interferes with 
the IL-2-medlated inductive signal. It should be noted 
here that the inhibition of induction of LAK cell activity 
contrasts with the effect of IL-4 on the IL-2-mediated 
growth promotion of T cells. IL-4 can either act in an 
additive or in a synergistic way with IL-2 in the promotion 
of T cell growth and does not inhibit the proliferation of 
T cells induced by IL-2 (17). Therefore, the inhibitory 
effect of IL-4 on the induction of LAK cell activity indi­
cates that the mechanism of IL-2-induced growth pro­
motion is different from the IL-2-induced activation of 
killer cell activity. This latter notion is supported by 
findings reported previously that antibodies against the 
55-kDa Tac Ag, although inhibiting T cell growth pro­
motion by IL-2, do not affect the induction of LAK cell 
activity mediated by IL-2 (10, 11).
Recently, the existence of a second IL-2-binding protein 
that binds IL-2 with an intermediate affinity has been 
reported (12-15). A complex of this 73-kDa receptor (re­
ferred to as p70) with the Tac protein has a high affinity 
for IL-2, whereas the Tac protein itself has a low affinity. 
It has been shown that fresh NK cells express the p70 
protein (12-14). Interestingly, Siegel et al. (14) recently 
reported evidence suggesting that the p70 protein me­
diates the initial phase of the induction of LAK cells. 
Activation of LAK cell precursors via this protein induces 
the formation of high affinity receptors that are involved 
in proliferation and a further augmentation of LAK cell 
activity (14). If this scheme is correct, IL-4 could interfere 
with signal transduction via the p70 protein. We specu­
late that once the high affinity receptor is expressed, IL- 
4 is unable to influence LAK cell activity. This idea would 
explain why IL-4 does not block the generation of Ag- 
specific cytotoxicity, inasmuch as in that situation the
high affinity receptor appears on the cell membrane after 
the interaction of Ag with the TCR/CD3 complex. We 
have observed that the expression of Tac on T cell cul­
tures stimulated by mitogens or alloantigens is not af­
fected by IL-4. Moreover, IL-4 has no inhibitory or stim­
ulatory effects on Tac expression by T cell lines (H, Yssel 
and H. Spits unpublished observation), supporting the 
notion that IL-4 does not affect the induction of Tac by 
occupancy of the TCR/CD3 complex. Thus, IL-4 could 
prevent the transition of p70+, Tac"" cells to p70+, Tac+ 
cells as a consequence of activation by IL-2, but not after 
activation via the TCR/CD3 complex. This hypothesis 
would predict that IL-4 prevents the IL-2-mediated ap­
pearance of Tac. After 3 days, however, Tac expression 
on IL-2-activated cells is not significantly higher than on 
IL-4-plus-IL-2-activated cells, In preliminary experi­
ments however, we have found that, after 7 days, Tac 
expression is indeed higher on IL-2 than on IL-4-plus-IL- 
2-activated cells (results not shown). This finding sug­
gests that the kinetics of Tac appearance as a conse­
quence of IL-2 activation is retarded, compared with the 
induction of LAK cell activity. This point is currently 
under investigation.
We have found that addition of IL-4 to MLC resulted in 
strong inhibition of cytotoxic activity against K-562 and 
MEWO cells generated in MLC. These findings, along 
with the observation that IL-4 inhibits the IL-2-induced ' 
LAK cell activity, suggest that non-specific cytotoxic ac­
tivity in MLC is induced by IL-2 produced by the respond- 
ing T cell blasts. In contrast, specific cytotoxic activity, 
generated in a MLC in the presence of IL-4, was increased 
compared with the specific cytotoxicity generated in the 
presence of IL-2 or in medium only. These results dem­
onstrate that IL-4 is not an inhibitor of the induction of 
cellular cytotoxicity in general, but that this ability is 
restricted to the induction of LAK cell activity. Presently, 
the mechanism of the enhancement of specific CTL ac­
tivity by IL-4 remains to be determined. MLC carried out 
in the presence of IL-4 contain 10 to 20% more CD8+ cells 
than the MLC in medium only, but it is unclear whether 
this is the reason for the augmented CTL activity. In the 
secondary MLC, IL-2 and IL-4 clearly augmented the 
number of responding cells and enhanced the CTL activ­
ity per culture. Moreover IL-4 also stimulated slightly the 
CTL activity per cell in the secondary MLC. Because IL-2 
and other lymphokines are produced in MLC, the exact 
role of IL-4 in the generation of CTL activity is difficult 
to assess. It is, for example, possible that IL-4 mediates 
its augmenting effect on CTL activity in combination with 
other lymphokines, such as IL-2. It is therefore premature 
to conclude from our present data that IL-4 is a major 
helper factor in the generation of Ag-specific CTL.
Presently we are performing a clonal analysis of CTL 
clones isolated in IL-4 compared with those isolated in 
IL-2 to determine the effects of these lymphokines on the 
level of a single cell. Preliminary results do not reveal 
significant differences in the clonal efficiencies and in 
the cytotoxic activities against the specific stimulator 
cells of the isolated CTL clones in IL-2 or IL-4 (X. Paliard 
and H. Spits unpublished observation). It is nevertheless 
noteworthy that our findings with bulk MLC cultures are 
in line with those of Widmer and Grabstein in a mouse 
model (29). These authors observed that IL-4 can enhance 
specific cytotoxic activity in mouse MLC. Thus, it seems
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that mouse and human IL-4 share the ability to augment 
Ag-specific CTL activity. However, IL-4 has a different 
effect on the generation of LAK cell activity in the murine 
system than in the human. Mulé et al. (31) found that 
murine IL-4 induces LAK cell activity in spleen cells. 
Moreover, IL-4 enhanced the induction of LAK cell activ­
ity by sub-optimal doses of IL-2. The reason for the 
discrepancy between our results and those of Mulé et al. 
is unclear. Apart from the possibility that the ability of 
IL-4 to block the induction of LAK cell activity is species 
restricted, it might be possible that mouse spleen cells 
contain already activated precursor cells. As shown here, 
IL-4 does not inhibit the activity once the precursor LAK 
cells are activated. It would be interesting to see whether 
IL-4 also induces LAK cell activity in mouse PBL. We 
have found that IL-4 inhibits the IL-2-induced LAK cell 
activity in spleen cells, indicating that human spleen 
cells do not contain activated LAK cell precursors.
It is possible that the IL-4-mediated suppression of the 
generation of LAK cell activity is relevant in the regula­
tion of Ig production, inasmuch as it has been shown 
that NK cells can suppress Ig synthesis in a non-specific 
way (32, 33). It is tempting to speculate that IL-4 produc­
tion during T cell-B cell collaboration prevents unwanted 
suppression by activated killer cells induced by IL-2.
Note added in proof. After this manuscript was com­
pleted, we became aware that Widmer et al. (34) have 
reported findings similar to ours. The data reported here 
confirm and extend the findings of Widmer et al. (34).
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